JP2022528562A5 - - Google Patents

Info

Publication number
JP2022528562A5
JP2022528562A5 JP2021560410A JP2021560410A JP2022528562A5 JP 2022528562 A5 JP2022528562 A5 JP 2022528562A5 JP 2021560410 A JP2021560410 A JP 2021560410A JP 2021560410 A JP2021560410 A JP 2021560410A JP 2022528562 A5 JP2022528562 A5 JP 2022528562A5
Authority
JP
Japan
Prior art keywords
methyl
imidazo
carboxamide
pyridine
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560410A
Other languages
English (en)
Japanese (ja)
Other versions
JP7762957B2 (ja
JP2022528562A (ja
Filing date
Publication date
Priority claimed from GBGB1904848.7A external-priority patent/GB201904848D0/en
Priority claimed from GBGB1912603.6A external-priority patent/GB201912603D0/en
Priority claimed from GBGB1919095.8A external-priority patent/GB201919095D0/en
Application filed filed Critical
Priority claimed from PCT/GB2020/050898 external-priority patent/WO2020201773A1/en
Publication of JP2022528562A publication Critical patent/JP2022528562A/ja
Publication of JP2022528562A5 publication Critical patent/JP2022528562A5/ja
Application granted granted Critical
Publication of JP7762957B2 publication Critical patent/JP7762957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560410A 2019-04-05 2020-04-03 Ｍｅｔｔｌ３阻害化合物 Active JP7762957B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1904848.7 2019-04-05
GBGB1904848.7A GB201904848D0 (en) 2019-04-05 2019-04-05 Inhibitory compounds
GB1912603.6 2019-09-02
GBGB1912603.6A GB201912603D0 (en) 2019-09-02 2019-09-02 Inhibitory compounds
GB1919095.8 2019-12-20
GBGB1919095.8A GB201919095D0 (en) 2019-12-20 2019-12-20 Inhibitory compounds
PCT/GB2020/050898 WO2020201773A1 (en) 2019-04-05 2020-04-03 Mettl3 inhibitory compounds

Publications (3)

Publication Number Publication Date
JP2022528562A JP2022528562A (ja) 2022-06-14
JP2022528562A5 true JP2022528562A5 (https=) 2023-04-10
JP7762957B2 JP7762957B2 (ja) 2025-10-31

Family

ID=70285722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560410A Active JP7762957B2 (ja) 2019-04-05 2020-04-03 Ｍｅｔｔｌ３阻害化合物

Country Status (5)

Country Link
US (2) US12358915B2 (https=)
EP (1) EP3946618A1 (https=)
JP (1) JP7762957B2 (https=)
CN (1) CN113905787A (https=)
WO (1) WO2020201773A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
WO2022074379A1 (en) * 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
US11944608B2 (en) * 2020-10-26 2024-04-02 New York University Targeting RNA viruses using inhibitors of METTL3
CA3219183A1 (en) * 2021-05-17 2022-11-24 Amedeo Caflisch N6-adenosine-methyltransferase inhibitors in cancer treatment
GB202107905D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Processes for the preparation of inhibitory compounds
GB202107907D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
CN116514805A (zh) * 2021-12-10 2023-08-01 成都先导药物开发股份有限公司 Mettl3抑制剂化合物
CN118660890A (zh) * 2022-02-11 2024-09-17 西藏海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途
CN114869891A (zh) * 2022-04-28 2022-08-09 复旦大学附属中山医院 Mettl3抑制剂在制备治疗肝癌药物中的应用
CN117045801A (zh) * 2022-05-13 2023-11-14 中国科学院广州生物医药与健康研究院 m6A RNA甲基化酶抑制剂与免疫检查点抑制剂联合治疗肿瘤
CN117720533A (zh) * 2022-09-16 2024-03-19 北京华益健康药物研究中心 Mettl3抑制剂化合物及其药物组合物和应用
WO2024107763A1 (en) * 2022-11-16 2024-05-23 University Of Zurich N6-adenosine-methyltransferase protacs and methods of use thereof
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
CN120731203A (zh) 2023-01-20 2025-09-30 艾匹克治疗公司 作为mettl3抑制剂的哌啶衍生物
AU2024244637A1 (en) 2023-03-30 2025-10-16 Aqemia Novel mettl3 inhibitors and use thereof in therapy
GB202316683D0 (en) * 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025237957A1 (en) 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
WO2026067558A1 (zh) * 2024-09-25 2026-04-02 中国科学院上海药物研究所 稠合双环类化合物及其制备方法、组合物和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946031A (en) 1973-10-04 1976-03-23 Syntex Inc. 2-Substituted-1,2,4-thiadiazolo-[2,3-a]-benzimidazoles
US3880874A (en) * 1973-10-04 1975-04-29 Syntex Inc 2-Substituted -1,2,4-thiadiazolo-(2,3-a)benzimidazoles and process for their preparation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
ATE380176T1 (de) * 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
JP2004517080A (ja) * 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
JP2005509003A (ja) * 2001-11-09 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
CL2008001626A1 (es) * 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
FR2925901B1 (fr) * 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
US20200129596A1 (en) * 2017-03-13 2020-04-30 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT
CN115151540A (zh) * 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物

Similar Documents

Publication Publication Date Title
JP2022528562A5 (https=)
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
JP5847087B2 (ja) オレキシン受容体調節因子としての縮合複素環式化合物
US7759337B2 (en) Phthalazine compounds and methods of use
AU2005267884B2 (en) Potassium channel inhibitors
EP2491031B1 (en) Fused heterocyclic compounds as orexin receptor modulators
CA2900855C (en) Aminopyrimidinyl compounds
RU2434013C2 (ru) Гетероциклические ингибиторы янус-киназы 3
DK2225238T3 (en) Derivatives of 6,7-dihydro-5H-imidazoý1,2- imidazol-3-carboxylic acid amides.
CA2610888A1 (en) Inhibitors of akt activity
MX2015004151A (es) Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
KR20170066566A (ko) Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도
TR201910730T4 (tr) Yeni pirazolo pirimidin deriveleri ve bunların malt1 inhibitörleri olarak kullanımı.
WO2008085302A1 (en) Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
MX2013003913A (es) Compuestos de furo [3, 2-d] pirimidina.
RU2014119244A (ru) Гетероциклические соединения и способы их использования
WO2007084728A2 (en) 2-imino-benzimidazoles
US20150328224A1 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
EA037598B1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
US8367671B2 (en) Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
EA019990B1 (ru) ПРОИЗВОДНЫЕ АМИДОВ 6,7-ДИГИДРО-5H-ИМИДАЗО[1,2-a]ИМИДАЗОЛ-3-КАРБОНОВОЙ КИСЛОТЫ
CA3236550A1 (en) Spirotricycle ripk1 inhibitors and methods of uses thereof
HK1145683B (en) DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES
HK1175462B (en) Fused heterocyclic compounds as orexin receptor modulators